How US peptide regulation actually works

“Peptide” is not a legal category

Insulin is a peptide. So are semaglutide and tirzepatide, octreotide, desmopressin and oxytocin. All are FDA-approved drugs, sold in ordinary pharmacies, covered by insurance. Nothing about the chemical class makes a substance illegal or suspect.

What separates those from BPC-157 or TB-500 is simple: someone ran the trials, filed the application, and the FDA approved it. That is the whole difference. When coverage treats “peptides” as one regulatory object, it is describing a marketing category, not a legal one.

August 2026 supplied the sharpest illustration of this. The FDA approved Takeda’s Orzeyful (oveporexton) for narcolepsy type 1 — the first drug for the disorder as a whole, and the first to work by activating the orexin receptor directly. Orexin is a neuropeptide, and narcolepsy type 1 is what happens when the cells that produce it are lost; but the medicine that finally addressed that deficiency is a small molecule, not a peptide, because peptides swallowed as tablets are broken down in the gut. The agency added that Orzeyful “has been recommended for scheduling under the Controlled Substances Act and will be lawful to market following the scheduling decision issued by the Drug Enforcement Agency”. So the approved treatment for a neuropeptide-deficiency disease will be a controlled substance, while BPC-157 and TB-500 — approved for nothing — sit on no schedule at all. Chemical class predicted none of that. The approval landed twelve days after the advisory committee declined to recommend DSIP for indications including narcolepsy.

Three regimes, three different questions

Most arguments about whether a peptide is “legal” are three questions wearing one coat.

Controlled-substance law asks whether possession is a scheduling offense. For the peptides we track the answer is no — none is in Schedules I through V.

Federal drug law asks whether a product may be sold for human use. Here the answer is usually that it may not: an unapproved new drug under the Federal Food, Drug, and Cosmetic Act.

Compounding law asks whether a licensed pharmacy may prepare it. That depends on lists, and on rulemaking that mostly has not happened.

A substance can be clear under the first and prohibited under the other two. That is where most research peptides sit, and it is why “is it legal” has no one-word answer.

503A and 503B are not the same pharmacy

Section 503A covers traditional compounding: one preparation, one identified patient, one prescription. A pharmacy mixing a cream for a named patient is 503A.

Section 503B covers outsourcing facilities. They compound in batches without patient-specific prescriptions, and must meet manufacturing standards close to a drug maker’s.

The two have separate lists of permitted bulk substances. A substance cleared for one is not thereby cleared for the other. Coverage that says “peptides were approved for compounding” almost never says which section it means — and the difference decides who may lawfully make anything at all.

What the bulks list is, and what April 2026 actually did

A substance that is not an approved drug can still be compounded under 503A if it complies with a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A bulks list.

Substances nominated for that list wait in interim categories. Category 1 means FDA does not intend to act against a pharmacy compounding with the substance while the evaluation continues. Category 2 means FDA identified significant safety risks and does not extend that policy. Category 3 means the nomination lacked enough information to evaluate. The categories still exist, but FDA stopped assigning them to substances nominated on or after 7 January 2025 — anything nominated since then has no interim shelter at all.

In April 2026 a dozen peptides left Category 2. Not because the FDA cleared them: because the parties that nominated them withdrew the nominations. Leaving Category 2 is not arriving at Category 1. The substances moved from “reviewed and flagged” to “not under consideration”, which is a weaker position, not a stronger one. Nothing became compoundable that day.

Category 2 now holds six substances in total, and the only peptide among them is Kisspeptin-10.

Why rulemaking takes years

A favorable advisory vote starts a process. It does not end one. The FDA must publish a proposed rule, take public comments, review them, and issue a final rule.

The record is more informative than any estimate. FDA solicited nominations in 2015. A final rule in February 2019 placed six substances on the 503A list and declined four others. A further proposed rule followed in September 2019, covering five substances for inclusion and 26 for exclusion — and as of the agency’s own page in May 2026, that proposed rule had still not been finalized.

Seven years is the number to hold in mind when someone says access is coming soon.

States are enforcing on their own

Federal silence is not national silence — but the documented state record is narrower than it is usually described. Two states have acted in public, and both acted under ordinary consumer-protection and licensing law rather than under anything written for peptides.

Connecticut sued Triggered Brand, a distributor selling “research grade” semaglutide and tirzepatide direct to consumers with no prescription and no medical oversight, in May 2025 under the Connecticut Unfair Trade Practices Act and the state’s unlicensed-pharmacy statutes. The case settled in August 2025 with a $300,000 judgment, most of it suspended, and an agreement to stop selling. In November 2025 the Alabama attorney general obtained a temporary restraining order and an asset freeze against a Cullman infusion clinic that had injected patients with research-grade tirzepatide and semaglutide while presenting it as pharmaceutical grade, under that state’s Deceptive Trade Practices Act.

Both of those cases concerned GLP-1 drugs that have approved counterparts — not the peptides now under 503A review. The one state measure that plainly reaches those came in May 2026, when the Alabama Board of Medical Examiners issued an official notice directing physicians, physician assistants, certified registered nurse practitioners and certified nurse midwives not to advise, recommend, supply, prescribe, administer, compound or dispense non-FDA-approved research-grade peptides, and not to delegate any of it to staff. The notice names no individual peptide, so it reaches BPC-157 and TB-500 as readily as semaglutide, and it states that a signed patient consent form does not reduce the provider’s liability. It is a notice to licensees rather than a statute — but it is the clearest signal yet from a state board that the licensing risk sits with the prescriber, not only with the seller.

Other states move more quietly, through pharmacy board minutes and advisories to licensees rather than public cases. So far the public actions have targeted selling, marketing and administration rather than individual possession, and enforcement is patchy and state-by-state. Patchy is not the same as permitted.

The anti-doping system is separate, and stricter

WADA’s list is not derived from FDA status and does not move with it. An athlete can face a four-year ban for a substance a pharmacy may lawfully compound.

WADA sorts banned substances into two groups, and the difference only matters after a positive test. Specified Substances are ones an athlete might plausibly have taken without meaning to cheat. If they can show how it got into their system and that they were not chasing an advantage, the ban can be cut — sometimes to a reprimand. Non-Specified substances get no such benefit of the doubt: the starting point is four years, and reductions are hard to win. Both groups are equally prohibited. The difference is what happens afterward.

Everything in section S0 — substances with no approval anywhere — is Specified. Most of what sits in sections S1 through S9 is not. BPC-157 is in S0, and was the first substance ever named there by example. TB-500 is in S2.3, as a thymosin-β4 derivative. Both are prohibited at all times; their sanction exposure differs.

One more point is consistently missed: a violation does not require a positive test. Use, attempted use and possession each count on their own, and can be established from records or admissions.

Outside the US

Rules change at the border, and not in the direction people expect. We have begun covering European jurisdictions on separate pages, with several already published. We do not publish guidance on obtaining anything, anywhere.

Primary sources: FDA, “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act” and “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A”, both current as of 14 May 2026 · final rule of February 2019 and proposed rule of September 2019 on the 503A bulks list · FDA interim policy on compounding using bulk drug substances (guidance, January 2025) · sections 503A and 503B of the FD&C Act · Controlled Substances Act schedules · WADA 2026 Prohibited List, sections S0 and S2 · Connecticut Attorney General, action against Triggered Brand (complaint May 2025; settlement announced August 2025) · Alabama Attorney General, suit and temporary restraining order against Aurora IV and Wellness (November 2025) · Alabama Board of Medical Examiners, official notice on the prescribing of non-FDA-approved (research-grade) peptides (May 2026) · FDA press announcement of 5 August 2026, “FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms” (Orzeyful / oveporexton).